Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Primary Purpose
Acne Vulgaris
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
IDP-120 Gel
IDP 120 Component A Gel
IDP 120 Component B Gel
IDP 120 Vehicle Gel
Sponsored by
About this trial
This is an interventional treatment trial for Acne Vulgaris
Eligibility Criteria
Key Inclusion Criteria:
- Male or female at least 9 years of age and older;
- Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit)
- Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at screening visit, and a negative urine pregnancy test at baseline visit.
- Subjects must be willing to comply with study instructions and return to the clinic for required visits. Subjects under the age of consent must be accompanied by the parent or legal guardian at the time of assent/consent signing.
- If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
Key Exclusion Criteria:
- Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
- Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis.
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
- Subjects with a facial beard or mustache that could interfere with the study assessments.
Sites / Locations
- Valeant Site 15
- Valeant Site 13
- Valeant Site 16
- Valeant Site 14
- Valeant Site 02
- Valeant Site 21
- Valeant Site 23
- Valeant Site 09
- Valeant Site 24
- Valeant Site 11
- Valreant Site 05
- Valeant Site 06
- Valeant Site 01
- Valeant Site 17
- Valeant Site 22
- Valeant Site 04
- Valeant Site 07
- Valeant Site 12
- Valeant Site 18
- Valeant Site 25
- Valeant Site 10
- Valeant Site 03
- Valeant Site 08
- Valeant Site 20
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
IDP-120 Gel
IDP-120 Component A Gel
IDP-120 Component B Gel
IDP-120 Vehicle Gel
Arm Description
IDP-120 Gel is a combination treatment
IDP-120 Monad Gel of Component A
IDP-120 Monad Gel of Component B
IDP-120 Vehicle Gel
Outcomes
Primary Outcome Measures
Percent of subjects achieving clear or almost clear on the Evaluator's Global Severity Score.
Percent of subjects who achieve at least a two-grade reduction from Baseline and are Clear or Almost Clear at Week 12 in the Evaluator's Global Severity Score.
Secondary Outcome Measures
Full Information
NCT ID
NCT03003247
First Posted
May 6, 2016
Last Updated
December 14, 2017
Sponsor
Bausch Health Americas, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03003247
Brief Title
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Official Title
A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
November 2015 (Actual)
Primary Completion Date
August 31, 2016 (Actual)
Study Completion Date
September 30, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bausch Health Americas, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Detailed Description
A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
364 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IDP-120 Gel
Arm Type
Experimental
Arm Description
IDP-120 Gel is a combination treatment
Arm Title
IDP-120 Component A Gel
Arm Type
Active Comparator
Arm Description
IDP-120 Monad Gel of Component A
Arm Title
IDP-120 Component B Gel
Arm Type
Active Comparator
Arm Description
IDP-120 Monad Gel of Component B
Arm Title
IDP-120 Vehicle Gel
Arm Type
Placebo Comparator
Arm Description
IDP-120 Vehicle Gel
Intervention Type
Drug
Intervention Name(s)
IDP-120 Gel
Other Intervention Name(s)
Component A + B
Intervention Description
IDP-120 Gel is a combination product
Intervention Type
Drug
Intervention Name(s)
IDP 120 Component A Gel
Other Intervention Name(s)
Component A
Intervention Description
Monad of Component A
Intervention Type
Drug
Intervention Name(s)
IDP 120 Component B Gel
Other Intervention Name(s)
Component B
Intervention Description
Monad of Component B
Intervention Type
Drug
Intervention Name(s)
IDP 120 Vehicle Gel
Other Intervention Name(s)
Vehicle
Intervention Description
Vehicle
Primary Outcome Measure Information:
Title
Percent of subjects achieving clear or almost clear on the Evaluator's Global Severity Score.
Description
Percent of subjects who achieve at least a two-grade reduction from Baseline and are Clear or Almost Clear at Week 12 in the Evaluator's Global Severity Score.
Time Frame
12 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
9 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Key Inclusion Criteria:
Male or female at least 9 years of age and older;
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit)
Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at screening visit, and a negative urine pregnancy test at baseline visit.
Subjects must be willing to comply with study instructions and return to the clinic for required visits. Subjects under the age of consent must be accompanied by the parent or legal guardian at the time of assent/consent signing.
If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
Key Exclusion Criteria:
Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis.
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
Subjects with a facial beard or mustache that could interfere with the study assessments.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anya Loncaric
Organizational Affiliation
Valeant Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Valeant Site 15
City
Encino
State/Province
California
ZIP/Postal Code
91316
Country
United States
Facility Name
Valeant Site 13
City
Lake Mary
State/Province
Florida
ZIP/Postal Code
32746
Country
United States
Facility Name
Valeant Site 16
City
Miami
State/Province
Florida
ZIP/Postal Code
33101
Country
United States
Facility Name
Valeant Site 14
City
Tampa
State/Province
Florida
ZIP/Postal Code
33601
Country
United States
Facility Name
Valeant Site 02
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Valeant Site 21
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30302
Country
United States
Facility Name
Valeant Site 23
City
South Bend
State/Province
Indiana
ZIP/Postal Code
46601
Country
United States
Facility Name
Valeant Site 09
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48204
Country
United States
Facility Name
Valeant Site 24
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55401
Country
United States
Facility Name
Valeant Site 11
City
Saint Joseph
State/Province
Missouri
ZIP/Postal Code
64502
Country
United States
Facility Name
Valreant Site 05
City
New York
State/Province
New York
ZIP/Postal Code
10001
Country
United States
Facility Name
Valeant Site 06
City
New York
State/Province
New York
ZIP/Postal Code
10002
Country
United States
Facility Name
Valeant Site 01
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States
Facility Name
Valeant Site 17
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27268
Country
United States
Facility Name
Valeant Site 22
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43085
Country
United States
Facility Name
Valeant Site 04
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37901
Country
United States
Facility Name
Valeant Site 07
City
Austin
State/Province
Texas
ZIP/Postal Code
73301
Country
United States
Facility Name
Valeant Site 12
City
Austin
State/Province
Texas
ZIP/Postal Code
78701
Country
United States
Facility Name
Valeant Site 18
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78204
Country
United States
Facility Name
Valeant Site 25
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Facility Name
Valeant Site 10
City
Winnepeg
State/Province
Manitoba
ZIP/Postal Code
R2C 0A1
Country
Canada
Facility Name
Valeant Site 03
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 0A1
Country
Canada
Facility Name
Valeant Site 08
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2J 1L9
Country
Canada
Facility Name
Valeant Site 20
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N9A 2S6
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
We'll reach out to this number within 24 hrs